The β 2 -adrenergic receptor (β 2 AR) is a G protein-coupled 10 receptor (GPCR) and a well-explored target. Here, we report the discovery 11 of 13 ligands, ten of which are novel, of this particular GPCR. They have 12 been identified by similarity-and substructure-based searches using 13 multiple ligands, which were described in an earlier study, as starting 14 points. Of note, two of the molecules used as queries here distinguish 15 themselves from other β 2 AR antagonists by their unique scaffold. The 16 molecules described in this work allow us to explore the ligand space 17 around the previously reported molecules in greater detail, leading to 18 insights into their structure−activity relationship. We also report 19 experimental binding and selectivity data and putative binding modes for 20 the novel molecules. 21 
(GPCR) family are flexible heptahelical bundles trans-24 ferring signals from the outside to the inside of a cell. This is 25 achieved by a conformational change of the receptor upon 26 binding of a signaling molecule to a cavity located at the 27 extracellular end between the seven helices. GPCRs are 28 expressed in almost all tissues, 1 and it is thus not surprising 29 that approximately 1/3 of present-day drugs interact with a 30 GPCR. 2 Among these receptors, the β 2 -adrenergic receptor 31 (β 2 AR) is considered a prototypical representative and has been 32 investigated for more than 60 years. It was also the first 33 pharmacologically relevant GPCR to succumb to crystallization 34 in 2007. 3,4 35 In a previous work, 5 we have identified six ligands (originally 36 labeled 1−6, and referred to as Q1−Q6 in this work to avoid 37 confusion, Chart S1) of the β 2 AR through in silico docking 38 studies, with affinities ranging from 9 nM to 3.2 μM. Notably, 39 these included two molecules (5 and 6 in ref 5, denoted as Q5 40 and Q6, respectively, in the following) that did not follow the 41 classical adrenaline-based scaffold. 6 This was remarkable, as 42 nobody had discovered these scaffolds earlier, despite more 43 than six decades of medicinal chemistry in this area. Building 44 upon the discovery of the six ligands, we wanted to expand 45 chemical space around them. In particular, we wanted to 46 investigate the two ligands with unusual scaffolds by employing 47 in silico similarity and substructure searches in the ZINC 7 48 database. Candidate molecules identified in either way were 49 then docked into the β 2 AR, in order to ascertain that their 50 binding modes were consistent. Here we report the results of 51 this combined ligand-and structure-based screen, which also 52 provides insights into the structure−activity relationship (SAR) 53 of molecules Q5 and Q6 and their derivatives. 54 The similarity screen among the 8.5 million molecules of the 55 ZINC database resulted in 6363 molecules, which were 56 distributed across the six query molecules as shown in Table   57 S1. From the substructure-based screen, approximately 653 000 58 hits emerged. Duplicates were removed from both sets. After 59 docking, 5838 and 587 099 molecules remained, respectively, 60 and the top-scoring 500 of each run were visually inspected. 61 After weeding out molecules with artificially inflated scores due 62 to the absence of corrective terms in present-day scoring 63 functions, e.g., unfavorable desolvation contributions or 64 unsatisfied hydrogen-bond donors, during this inspection, we 65 were left with eight and nine molecules from the similarity and 66 substructure searches, respectively. These were acquired from 67 their respective vendors for further experimental testing (Table   68   S5 ). Three compounds (1, 2, and 3) contained a biaryl moiety 69 and a charged amine and thus resembled the classical motif of a 70 β 2 binder. Indeed, a thorough literature search revealed that 71 t1 these compounds had been described before (Table 1 ; by the 72 time of selection, these compounds had not been annotated in 73 ChEMBL 8 ). To analyze the selectivity of the compounds, we 74 also evaluated them against the closely related β 1 AR. The Supporting Information for assay validation and Table S2 for 80 inactive compounds). This assay also demonstrated that 81 compound 3 had very high affinity (pK D 9.01 at β 1 AR and 82 pK D 10.45 at β 2 AR) and was therefore 28-fold β 2 -selective f1 83 ( Figure 1a ,c, Table 1 ). While the remaining compounds had 84 relatively poor affinity in comparison to 3, many of them, e.g., 85 1, 2, 10, 11 and 13, inhibited [ 3 H](−)CGP 12177 binding to 86 yield measurable affinity values (Figure 1b ,d, Table 1 ). 87 Next, characteristics of ligands were examined in a functional 88 assay, namely, CRE-gene transcription. The ability of ligands to 89 stimulate a response (intrinsic efficacy) was assessed, but also, 90 given that the affinity of many of the ligands to inhibit 91 [ 3 H](−)CGP 12177 binding were at the very limit of the 92 binding assay, the ability of ligands to inhibit f unctional 93 responses was also evaluated, thus giving a totally independent 94 measure of affinity from that achieved in the binding assay. Figure S1 , Table S3 ). For some compounds, e.g., 1, 2, Supporting   Table 1 . continued a Selectivity: β 2 /β 1 = K D (β 2 )/K D (β 1 ) b Apparent K D values: here the maximum concentration of the compound was not sufficient to fully inhibit specific binding; however, the majority of specific binding was inhibited allowing an apparent measure of affinity. For ligands with less than 50% inhibition of specific binding, the IC 50 value could not be determined and thus a K D value could not be calculated (n.c.). c US 20090163545. 
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Letter 116 Information). At 2 μM, 10 was still able to cause a rightward 117 shift of the cimaterol concentration response curve at the β 2 AR, 118 but not the β 1 AR, consistent with its β 2 -selectivity. The fall 119 from maximum of the concentration response to cimaterol 120 (most likely because the assay is at the limit of its capability) 121 means that an apparent K D is reported (calculated from the 122 shift of the lower part of the curve where the lines are parallel), 123 this apparent K D is however similar to the K D values obtained 124 from the binding assay, confirming that this is receptor-125 mediated and β 2 -selective. 126 Compound 3 on its own stimulated a partial agonist 127 response at both the β 1 -and β 2 AR. This response was inhibited 128 by CGP 20712A in the CHO-β 1 -cells with high affinity and by 129 ICI 118551 in the CHO-β 2 -cells ( Figure S1 , Table S3 ). 130 Furthermore, 3 was able to inhibit the cimaterol responses in 131 both cell lines in a manner consistent with that of a partial 132 agonist ( Figure S2 , Table S3 ). Finally, 3 inhibited the response 133 to fixed concentrations of cimaterol in both cell lines in a 134 manner consistent with competition at a single receptor 135 conformation 9 ( Figure S1 and Supplementary Procedures for 136 full details). 137 Altogether, the high affinity of CGP 20712A and ICI 118551 138 for the CHO-β 1 and CHO-β 2 cells confirm the presence of the 139 β 1 -and β 2 AR in the respective cell lines. Several of the 140 compounds (e.g., 16 and 17) did not interact with the 141 receptors in either the binding assay or functional assay up to 142 the maximum concentration possible for the compounds (20− 143 100 μM). Of the molecules with novel scaffolds, 10 and 11 144 show the highest affinities at pK D values of 6.05 and 5.31, 145 respectively, for the β 2 AR and are thus in a range comparable to 146 those of the established compounds 1 and 2. These compounds 147 did not induce a functional response in the receptor and are 148 therefore neutral antagonists. However, we emphasize that the 149 outcome of a virtual screening campaign in the manner 150 conducted here is the prediction of binding, not efficacy. Of the 151 novel compounds, 13 exhibited affinity in the binding as well as 152 in the functional assay with low micromolar activity. 153 The more traditional biaryl compounds 1, 2, and 3 display 154 the highest affinities at the β 2 AR, as was to be expected. In 155 particular, compound 3 was confirmed as a very high affinity 156 partial agonist at both receptors, but with some β 2 AR 157 selectivity. At the β 2 AR, the affinity measured by binding 158 (pK D 10.45) and the affinity measured as antagonism of the 159 cimaterol response (pK D 10.74) are very similar, confirming the 160 very high affinity ligand−receptor interaction. The partial 161 agonist was itself antagonized by ICI 118551 (yielding a similar 162 pK D for ICI 118551 as that for antagonism of the cimaterol 163 response), confirming that signaling is indeed occurring via the 164 β 2 AR. Compound 3 is therefore a very high affinity, weak 165 partial agonist of the human β 2 AR. Moreover, 3 was found to 166 be a partial agonist of the β 1 AR, with the agonist response 167 occurring through the primary catecholamine conformation of 168 the receptor (see Supplementary Results) . 169 These three molecules, 1, 2, and 3, were selected by 170 similarity to compounds Q2, Q3, and Q4, all of which contain a 171 biaryl moiety. Not unexpectedly, these hits not only show high 172 affinities but also highest similarities to known (again 173 exclusively biaryl-containing) compounds that are annotated 174 in the ChEMBL database (Table S6 ). This is encouraging with 175 respect to the performance of similarity screening methods and 176 the value of docking in identifying such compounds. However, 177 it also strongly emphasizes the need for methods that allow for 178 scaffold-hopping to fully explore the ligand space of a target. 179 By reducing the biaryl scaffold to a 2-ethoxy-ethylamine (S6 180 in Chart S2) for the substructure search, two more substances, 181 4 and 14, were identified. Compound 4 showed two-digit 182 micromolar affinity, whereas the inhibition by 14 was so weak 183 that no reliable affinity value could be calculated. Interestingly, 184 in 14 the nitrogen matched in the substructure search is the 185 one in the benzoxazine portion, not the exocyclic amine. 186 Turning to the hits derived from reference molecules Q5 and 187 Q6, we note that they show a much lower Tanimoto similarity 188 of approximately 0.3 and below (when compared to molecules 189 from the ChEMBL database using ECFP4 fingerprints) than 190 the other hits reported in ref 5 (Table S6 ). This is in line with 191 the fact that these compounds are not based on the classical Six additional compounds could be identified on the basis of 209 the parent molecule Q6. All these molecules (6, 7, 8, 9, 12, and 210 13) share a benzofuran-based moiety, independent of whether 211 they originated from the substructure or the similarity search. 212 This moiety, namely, a 3-oxo-4-methyl-6-hydroxy-benzofuran, 213 is present in the parent molecule Q6, too, and can thus be 214 considered a "stable scaffold" in terms of SAR. All molecules 215 display affinity, with pK D values varying between 5.26 and 4.6. 216 Interestingly, 8, which is the substance with the weakest affinity 217 in this set, differs from 7 only by a methoxy group, which is 218 absent in 8. This methoxy group could act as an acceptor, 219 which is also present in all remaining molecules of this series as 220 (benzo-)furan or methoxy group. The role of this group is not 221 clearly evident from the docking predictions, but an interaction 222 with Thr195 ECL2 seems to be the most likely explanation 223 ( Figures S5 and S6) . 236 We have elaborated on six previously identified novel binders 237 of the β 2 AR through SAR-by-catalog. Using similarity and 238 substructure searches followed by a docking assessment of the 239 interactions of each compound and the receptor, 13 ligands of 240 the β 2 AR were verified experimentally. Ten of these molecules 241 are indeed novel ligands for the receptor, while the remaining
Letter 242 three turned out to have been described before. Based on this 243 data, several conclusions can be drawn. 244 First, the benzofuran scaffold of compound Q5 and the 245 benzothiazole scaffold of compound Q6 in ref 5 indeed 246 constitute novel chemotypes with derivatization potential for 247 this receptor. Especially the benzofuran series showed a 248 consistent SAR that is in agreement with the predicted binding 249 modes. This study can thus also provide retrospective evidence 250 that the predicted binding modes are indeed very likely correct. 251 The affinities of the novel compounds are not comparable with 252 those of highly optimized adrenaline-or biaryl-based scaffolds. 253 The latter are exemplified by Q1 with an affinity of 9 nM and 3 254 with its pK D of 10.74. However, the novel compounds can serve 255 as unprecedented starting points for further optimization. 256 Second, that the combination of similarity-and substructure-257 based searches with protein-structure-based docking constitutes 258 a powerful combination. This is manifest in the quite high hit 259 rate (more than 75% of the molecules bind with an affinity 260 below 100 μM) and the fact that we (re)discovered a molecule 261 with an affinity of only 35 pM. This compound is also known as 262 bipranol or berlafenone, an antiarrythmia drug. 263 In terms of selectivity, most of the compounds displaying an 264 affinity are mildly selective toward the β 2 AR. Again, 3 takes the 265 lead here at 28-fold selectivity for the β 2 AR. While other 266 compounds such as 1 and 2 still have at least 10-fold preference 267 toward the β 2 AR, all values are far below 100-fold, which for 268 some receptors is considered a ratio that is significant enough 269 to call a compound "selective". Moreover, highly optimized 270 compounds such ICI 118551 show affinity ratios that are closer 271 to 1000-fold. Interestingly, the top three compounds in terms 272 of selectivity all belong to the biaryl cluster of molecules. 273 Not unexpectedly, most of the compounds with measurable 274 affinity (with the exception of 3), turned out to be neutral 275 antagonists in the functional assay. This is consistent with what 276 we have seen in our previous study 5 and the fact that we have 277 been docking to an inactive conformation of the receptor. 3,4 278 Future studies will show to which affinities the novel 279 scaffolds can be optimized. It is also encouraging to have 280 confirmed that unbiased computational methods can present us 281 with novel molecules, even for target proteins as well-282 investigated as the β 2 AR. 283 ■ EXPERIMENTAL PROCEDURES 284 Substructure queries (Chart S2) were manually derived from the 285 original hits. Substructure and similarity searches were run on the 286 ZINC database 7 and docked to the β 2 AR (PDB 2RH1), as previously 287 described. 5 [ 3 H](−)CGP 12177 whole cell binding and CRE-SPAP 288 production assays were run using CHO-K1 cells expressing either the 289 human β 1 AR or the human β 2 AR as previously described. 10 
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